Funding for this research was provided by:
National Cancer Institute (NIH P30 CA023100)
National Institutes of Health (U01CA217885, U24CA220341, U24CA248457, P30CA023100)
Joan and Irwin Jacobs Fund
Received: 21 February 2021
Accepted: 29 September 2021
First Online: 12 October 2021
: This study was performed in accordance with UCSD IRB guidelines for the PREDICT protocol (NCT02478931) and for any investigational treatments or procedures for which patients gave consent. Waiver of consent was permitted by protocol and UCSD IRB for non-identifying retrospective data collection and data analysis.Approval for the Foundation Medicine study including a waiver of informed consent and a Health Insurance Portability and Accountability Act (HIPAA) waiver of authorization was obtained from the Western Institutional Review Board (Protocol No. 20152817).Written informed consent was obtained from all participants.The research followed the Declaration of Helsinki guidelines.
: Not applicable.
: RK has the following disclosure information: Stock and Other Equity Interests (IDbyDNA, CureMatch, Inc., and Soluventis); consulting or advisory role (Gaido, LOXO, X-Biotech, Actuate Therapeutics, Roche, NeoMed, Soluventis, and Pfizer); speaker’s fee (Roche); research funding (Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Guardant Health, Grifols, Konica Minolta, DeBiopharm, Boerhringer Ingelheim, and OmniSeq [all institutional]); board member (CureMatch, Inc and CureMetrix Inc.).AG receives consulting fees from Seattle Genetics and EUSA Pharma.GF and SS are employees at Foundation Medicine, Inc., a wholly owned subsidiary of Roche Holdings, Inc. and Roche Finance Ltd, and have equity interest in an affiliate of these Roche entities.The remaining author, TP, declares that he has no competing interests.